Reactive oxygen species (ROS) in cancer: from redox signaling and metabolic plasticity to therapeutic vulnerabilities

Abstract

Reactive oxygen species (ROS) are important regulators of cancer biology, acting as tumor-promoting signaling mediators and inducers of oxidative cell death. Oncogenic signaling, mitochondrial dysfunction, metabolic rewiring, and microenvironmental stress lead to increased basal ROS levels in cancer cells, resulting in a state of chronic oxidative pressure. Tumors develop adaptive antioxidant programs such as glutathione and thioredoxin, NADPH regeneration pathways, and sustained activation of the Nrf2–Keap1 axis to adapt to these conditions, leading to redox plasticity and “Nrf2 addiction” in some cancers. This adaptive rewiring allows malignant cells to sustain proliferative signaling while evading ROS-induced cytotoxicity and contributes substantially to therapeutic resistance. Despite the great promise of ROS-targeted therapies in preclinical studies, their translation into the clinic has been challenging for decades. Large antioxidant trials failed or even increased cancer risk. Many pro-oxidant therapies have limited efficacy due to a narrow therapeutic window, systemic toxicity, poor tumor selectivity, and a dynamic ability of tumors to reprogram antioxidant defenses. The significant intra-tumoral and spatial heterogeneity of redox status further complicates these constraints, where different tumor regions and cellular subpopulations exhibit different metabolic states, ROS thresholds, and sensitivities to ferroptosis. Emerging evidence indicates that ferroptosis, an iron-dependent cell death triggered by lipid peroxidation, is a significant therapeutic liability of redox-adapted tumors, particularly when antioxidant buffering systems like GPX4, system Xc^–, FSP1, or DHODH are impaired. This review discusses the molecular functions of ROS in tumor initiation, progression, immune regulation, metabolic adaptation, and therapeutic resistance and critically analyzes the reasons for clinical challenges in redox-targeted interventions despite extensive research. The review highlights the importance of adaptive antioxidant rewiring, redox-dependent metabolic flexibility, and the complexity of the tumor microenvironment in determining the therapeutic outcome. Finally, novel strategies in precision redox oncology are discussed, including biomarker-driven patient stratification, real-time redox profiling, ferroptosis-targeted therapies, and rational combination approaches with the aim to exploit tumor-specific redox vulnerabilities while minimizing toxicity to healthy tissues.

Keywords

ROS / oxidative stress / redox signaling / cancer metabolism / tumor microenvironment / targeted therapy

References

[1] Le Bras M, Clément MV, Pervaiz S, Brenner C. Reactive oxygen species and the mitochondrial signaling pathway of cell death. Histol Histopathol. 2005; 20: 205-20.

[2] Huang MZ, Li JY. Physiological regulation of reactive oxygen species in organisms based on their physicochemical properties. Acta Physiol. 2019; 228: e13351.

[3] Renschler MF. The emerging role of reactive oxygen species in cancer therapy. Eur J Cancer. 2004; 40: 1934- 40.

[4] Gupta SC, Hevia D, Patchva S, Park B, Koh W, Aggarwal BB. Upsides and Downsides of Reactive Oxygen Species for Cancer: The Roles of Reactive Oxygen Species in Tumorigenesis, Prevention, and Therapy. Antioxid Redox Signal. 2012; 16: 1295-322.

[5] Kietzmann T. Intracellular Redox Compartments: Mechanisms and Significances. Antioxid Redox Signal. 2010; 13: 395-8.

[6] Halvey PJ, Watson WH, Hansen JM, Go YM, Samali A, Jones DP. Compartmental oxidation of thiol-disulphide redox couples during epidermal growth factor signalling. Biochem J. 2005; 386: 215-9.

[7] Cross JV, Templeton DJ. Regulation of Signal Transduction Through Protein Cysteine Oxidation. Antioxid Redox Signal. 2006; 8: 1819-27.

[8] Templeton DJ, Aye MS, Rady J, Xu F, Cross JV. Purification of Reversibly Oxidized Proteins (PROP) Reveals a Redox Switch Controlling p38 MAP Kinase Activity. PLoS ONE. 2010; 5: e15012.

[9] Sosa V, Moliné T, Somoza R, Paciucci R, Kondoh H, LLeonart ME. Oxidative stress and cancer: An overview. Ageing Res Rev. 2013; 12: 376-90.

[10] Han C, Liu Y, Dai R, Ismail N, Su W, Li B. Ferroptosis and Its Potential Role in Human Diseases. Front Pharmacol. 2020; 11: 239.

[11] Sun Y, Lu Y, Saredy J, Wang X, Drummer Iv C, Shao Y, et al. ROS systems are a new integrated network for sensing homeostasis and alarming stresses in organelle metabolic processes. Redox Biol. 2020; 37: 101696.

[12] de la Lastra JMP, Andrés CMC, Munguira EB, Juan CA, Pérez-Lebeña E. Pathophysiology of reactive oxygen species (ROS). Arch Toxicol. 2026; 100: 475-513.

[13] He Z, Simon HU. A novel link between p53 and ROS. Cell Cycle. 2014; 12: 201-2.

[14] Scotcher J, Clarke DJ, Mackay CL, Hupp T, Sadler PJ, Langridge-Smith PRR. Redox regulation of tumour suppressor protein p53: identification of the sites of hydrogen peroxide oxidation and glutathionylation. Chem Sci. 2013; 4: 1257.

[15] Chen X, Song M, Zhang B, Zhang Y. Reactive Oxygen Species Regulate T Cell Immune Response in the Tumor Microenvironment. Oxidative Med Cell Longev. 2016; 2016: 1580967.

[16] Liang X, Weng J, You Z, Wang Y, Wen J, Xia Z, et al. Oxidative stress in cancer: from tumor and microenvironment remodeling to therapeutic frontiers. Mol Cancer. 2025; 24: 219.

[17] Shah R, Ibis B, Kashyap M, Boussiotis VA. The role of ROS in tumor infiltrating immune cells and cancer immunotherapy. Metabolism. 2024; 151: 155747.

[18] Singh R, Manna PP. Reactive oxygen species in cancer progression and its role in therapeutics. Explor Med. 2022; 3: 43-57.

[19] Li J, Lim JYS, Eu JQ, Chan AKMH, Goh BC, Wang L, et al. Reactive Oxygen Species Modulation in the Current Landscape of Anticancer Therapies. Antioxid Redox Signal. 2024; 41: 322-41.

[20] Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: How are they linked? Free Radic Biol Med. 2010; 49: 1603-16.

[21] Sabharwal SS, Schumacker PT. Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles' heel? Nat Rev Cancer. 2014; 14: 709-21.

[22] Jaganjac M, Milkovic L, Sunjic SB, Zarkovic N. The NRF2, Thioredoxin, and Glutathione System in Tumorigenesis and Anticancer Therapies. Antioxidants. 2020; 9: 1151.

[23] Perillo B, Di Donato M, Pezone A, Di Zazzo E, Giovannelli P, Galasso G, et al. ROS in cancer therapy: the bright side of the moon. Exp Mol Med. 2020; 52: 192-203.

[24] Maycotte P, Sarmiento-Salinas FL, García-Miranda A, Ovando-Ovando CI, Robledo-Cadena DX, Hernández-Esquivel L, et al. Metabolic and Oxidative Stress Management Heterogeneity in a Panel of Breast Cancer Cell Lines. Metabolites. 2024; 14: 435.

[25] Acharya A, Das I, Chandhok D, Saha T. Redox Regulation in Cancer: A Double-edged Sword with Therapeutic Potential. Oxidative Med Cell Longev. 2009; 3: 23-34.

[26] Yu Y, Liu S, Yang L, Song P, Liu Z, Liu X, et al. Roles of reactive oxygen species in inflammation and cancer. MedComm. 2024; 5: e519.

[27] Santos AL, Sinha S, Lindner AB. The Good, the Bad, and the Ugly of ROS: New Insights on Aging and Aging-Related Diseases from Eukaryotic and Prokaryotic Model Organisms. Oxidative Med Cell Longev. 2018; 2018: 1941285.

[28] Ummarino A, Calà N, Allavena P. Extrinsic and Cell-Intrinsic Stress in the Immune Tumor Micro-Environment. Int J Mol Sci. 2024; 25: 12403.

[29] Ray PD, Huang BW, Tsuji Y. Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cell Signal. 2012; 24: 981-90.

[30] Iqbal MJ, Kabeer A, Abbas Z, Siddiqui HA, Calina D, Sharifi-Rad J, et al. Interplay of oxidative stress, cellular communication and signaling pathways in cancer. Cell Commun Signal. 2024; 22: 7.

[31] O'Reilly A, Zhao W, Wickström S, Arnér ESJ, Kiessling R. Reactive oxygen species: Janus-faced molecules in the era of modern cancer therapy. J ImmunoTher Cancer. 2024; 12: e009409.

[32] Sorriento D. Oxidative Stress and Inflammation in Cancer. Antioxidants. 2024; 13: 1403.

[33] Mendoza EN, Ciriolo MR, Ciccarone F. Hypoxia-Induced Reactive Oxygen Species: Their Role in Cancer Resistance and Emerging Therapies to Overcome It. Antioxidants. 2025; 14: 94.

[34] Mahdavi Firouzabadi B, Gigliobianco MR, Joseph JM, Censi R, Di Martino P. Design of Nanoparticles in Cancer Therapy Based on Tumor Microenvironment Properties. Pharmaceutics. 2022; 14: 2708.

[35] Andrés CMC, Pérez de la Lastra JM, Andrés Juan C, Plou FJ, Pérez-Lebeña E. Superoxide Anion Chemistry-Its Role at the Core of the Innate Immunity. Int J Mol Sci. 2023; 24: 1841.

[36] Waltz F, Righetto RD, Lamm L, Salinas-Giegé T, Kelley R, Zhang X, et al. In-cell architecture of the mitochondrial respiratory chain. Science. 2025; 387: 1296-301.

[37] Quinlan CL, Perevoshchikova IV, Hey-Mogensen M, Orr AL, Brand MD. Sites of reactive oxygen species generation by mitochondria oxidizing different substrates. Redox Biol. 2013; 1: 304-12.

[38] Murphy MP. How mitochondria produce reactive oxygen species. Biochem J. 2008; 417: 1-13.

[39] Lambert AJ, Brand MD. Superoxide production by NADH:ubiquinone oxidoreductase (complex I) depends on the pH gradient across the mitochondrial inner membrane. Biochem J. 2004; 382: 511-7.

[40] Lenaz G. The Mitochondrial Production of Reactive Oxygen Species: Mechanisms and Implications in Human Pathology. IUBMB Life. 2008; 52: 159-64.

[41] Forquer I, Covian R, Bowman MK, Trumpower BL, Kramer DM. Similar Transition States Mediate the Q-cycle and Superoxide Production by the Cytochrome bc1 Complex. J Biol Chem. 2006; 281: 38459-65.

[42] de Almeida AJPO, de Oliveira JCPL, da Silva Pontes LV, de Souza Júnior JF, Gonçalves TAF, Dantas SH, et al. ROS: Basic Concepts, Sources, Cellular Signaling, and its Implications in Aging Pathways. Oxidative Med Cell Longev. 2022; 2022: 1225578.

[43] Shannon N, Gravelle R, Cunniff B. Mitochondrial trafficking and redox/phosphorylation signaling supporting cell migration phenotypes. Front Mol Biosci. 2022; 9: 925755.

[44] Alshaabi H, Heininger M, Cunniff B. Dynamic regulation of subcellular mitochondrial position for localized metabolite levels. J Biochem. 2019; 167: 109-17.

[45] Qin Z, Zhu X, Shen Y, Ling H, Ruan N, Ye W, et al. An emerging role of mitochondrial quality control in bone metabolism: from molecular mechanisms to targeted therapeutic interventions. Cell Mol Life Sci. 2025; 82: 291.

[46] Garza-Lombó C, Pappa A, Panayiotidis MI, Franco R. Redox homeostasis, oxidative stress and mitophagy. Mitochondrion. 2020; 51: 105-17.

[47] Macleod KF. Mitophagy and Mitochondrial Dysfunction in Cancer. Annu Rev Cancer Biol. 2020; 4: 41-60.

[48] Nakahara R, Maeda K, Aki S, Osawa T. Metabolic adaptations of cancer in extreme tumor microenvironments. Cancer Sci. 2023; 114: 1200-7.

[49] Chalifoux O, Faerman B, Mailloux RJ. Mitochondrial hydrogen peroxide production by pyruvate dehydrogenase and α-ketoglutarate dehydrogenase in oxidative eustress and oxidative distress. J Biol Chem. 2023; 299: 105399.

[50] Mailloux RJ, McBride SL, Harper ME. Unearthing the secrets of mitochondrial ROS and glutathione in bioenergetics. Trends Biochem Sci. 2013; 38: 592-602.

[51] Luo Y, Ma J, Lu W. The Significance of Mitochondrial Dysfunction in Cancer. Int J Mol Sci. 2020; 21: 5598.

[52] Bonora M, Missiroli S, Perrone M, Fiorica F, Pinton P, Giorgi C. Mitochondrial Control of Genomic Instability in Cancer. Cancers. 2021; 13: 1914.

[53] Suomalainen A, Nunnari J. Mitochondria at the crossroads of health and disease. Cell. 2024; 187: 2601-27.

[54] Park CB, Larsson NG. Mitochondrial DNA mutations in disease and aging. J Cell Biol. 2011; 193: 809-18.

[55] Juan CA, Pérez de la Lastra JM, Plou FJ, Pérez-Lebeña E. The Chemistry of Reactive Oxygen Species (ROS) Revisited: Outlining Their Role in Biological Macromolecules (DNA, Lipids and Proteins) and Induced Pathologies. Int J Mol Sci. 2021; 22: 4642.

[56] Isbel L, Grand RS, Schübeler D. Generating specificity in genome regulation through transcription factor sensitivity to chromatin. Nat Rev Genet. 2022; 23: 728-40.

[57] Xu L, Ma S, Qu M, Li N, Sun X, Wang T, et al. Parthanatos initiated by ROS-induced DNA damage is involved in intestinal epithelial injury during necrotizing enterocolitis. Cell Death Discov. 2024; 10: 345.

[58] Kračun D, Lopes LR, Cifuentes-Pagano E, Pagano PJ. NADPH oxidases: redox regulation of cell homeostasis and disease. Physiol Rev. 2025; 105: 1291-428.

[59] Serrander L, Cartier L, Bedard K, Banfi B, Lardy B, Plastre O, et al. NOX4 activity is determined by mRNA levels and reveals a unique pattern of ROS generation. Biochem J. 2007; 406: 105-14.

[60] Jiménez-Uribe AP, Gómez-Sierra T, Aparicio-Trejo OE, Orozco-Ibarra M, Pedraza-Chaverri J. Backstage players of fibrosis: NOX4, mTOR, HDAC, and S1P; companions of TGF-β. Cell Signal. 2021; 87: 110123.

[61] Weinberg F, Ramnath N, Nagrath D. Reactive Oxygen Species in the Tumor Microenvironment: An Overview. Cancers. 2019; 11: 1191.

[62] Blanchetot C, Boonstra J. The ROS-NOX Connection in Cancer and Angiogenesis. Crit Rev Eukaryot Gene Expr. 2008; 18: 35-45.

[63] Panday A, Sahoo MK, Osorio D, Batra S. NADPH oxidases: an overview from structure to innate immunity-associated pathologies. Cell Mol Immunol. 2014; 12: 5-23.

[64] Bhattacharyya S, Sinha K, Sil PC. Cytochrome P450s: Mechanisms and Biological Implications in Drug Metabolism and its Interaction with Oxidative Stress. Curr Drug Metab. 2015; 15: 719-42.

[65] Wang M, Xiao Y, Miao J, Zhang X, Liu M, Zhu L, et al. Oxidative Stress and Inflammation: Drivers of Tumorigenesis and Therapeutic Opportunities. Antioxidants. 2025; 14: 735.

[66] Zhao Y, Ye X, Xiong Z, Ihsan A, Ares I, Martínez M, et al. Cancer Metabolism: The Role of ROS in DNA Damage and Induction of Apoptosis in Cancer Cells. Metabolites. 2023; 13: 796.

[67] Wang Y, Qi H, Liu Y, Duan C, Liu X, Xia T, et al. The double-edged roles of ROS in cancer prevention and therapy. Theranostics. 2021; 11: 4839-57.

[68] Shen J, Dong J, Shao F, Zhao J, Gong L, Wang H, et al. Graphene Oxide Induces Autophagy and Apoptosis Via The ROS-Dependent AMPK/mTOR/ULK-1 Pathway in Colorectal Cancer Cells. Nanomedicine. 2022; 17: 591-605.

[69] Sun K, Gao L, Li S, Zheng J, Zhu Z, Zhi K, et al. Circ-CDK8 regulates SLC7A11-mediated ferroptosis by inhibiting miR-615-5p to promote progression in oral squamous cell carcinomas. Front Pharmacol. 2024; 15: 1432520.

[70] Furuhashi M. New insights into purine metabolism in metabolic diseases: role of xanthine oxidoreductase activity. Am J Physiol-Endocrinol Metab. 2020; 319: E827-34.

[71] Leyane TS, Jere SW, Houreld NN. Oxidative Stress in Ageing and Chronic Degenerative Pathologies: Molecular Mechanisms Involved in Counteracting Oxidative Stress and Chronic Inflammation. Int J Mol Sci. 2022; 23: 7273.

[72] Richette P, Frazier A, Bardin T. Impact of anti-inflammatory therapies, xanthine oxidase inhibitors and other urate-lowering therapies on cardiovascular diseases in gout. Curr Opin Rheumatol. 2015; 27: 170-4.

[73] Cremers CM, Jakob U. Oxidant Sensing by Reversible Disulfide Bond Formation. J Biol Chem. 2013; 288: 26489-96.

[74] Fill M, Copello JA. Ryanodine Receptor Calcium Release Channels. Physiol Rev. 2002; 82: 893-922.

[75] Olmos-Orizaba BE, Márquez-Ramírez CA, Garcia-Berumen CI, Villagómez AVH, Calderón-Cortés E, Saavedra-Molina A, et al. Avocado Oil Alleviates Renal Damage and decreases NADPH Oxidase Activity, Peroxynitrite Production and Mitochondrial Calcium Uptake in Hypertension Rats. FASEB J. 2019; 33: e33.

[76] Tolmacheva AS, Nevinsky GA. Essential Protective Role of Catalytically Active Antibodies (Abzymes) with Redox Antioxidant Functions in Animals and Humans. Int J Mol Sci. 2022; 23: 3898.

[77] Ranbhise JS, Singh MK, Ju S, Han S, Yun HR, Kim SS, et al. The Redox Paradox: Cancer’s Double-Edged Sword for Malignancy and Therapy. Antioxidants. 2025; 14: 1187.

[78] He F, Ru X, Wen T. NRF2, a Transcription Factor for Stress Response and Beyond. Int J Mol Sci. 2020; 21: 4777.

[79] Kitamura H, Takeda H, Motohashi H. Genetic, metabolic and immunological features of cancers with NRF2 addiction. FEBS Lett. 2022; 596: 1981-93.

[80] Wu T, Harder BG, Wong PK, Lang JE, Zhang DD. Oxidative stress, mammospheres and Nrf2-new implication for breast cancer therapy? Mol Carcinog. 2014; 54: 1494-502.

[81] Wu S, Lu H, Bai Y. Nrf2 in cancers: A double-edged sword. Cancer Med. 2019; 8: 2252-67.

[82] Torrente L, Maan G, Oumkaltoum Rezig A, Quinn J, Jackson A, Grilli A, et al. High NRF2 Levels Correlate with Poor Prognosis in Colorectal Cancer Patients and with Sensitivity to the Kinase Inhibitor AT9283 In Vitro. Biomolecules. 2020; 10: 1365.

[83] Bae T, Hallis SP, Kwak MK. Hypoxia, oxidative stress, and the interplay of HIFs and NRF2 signaling in cancer. Exp Mol Med. 2024; 56: 501-14.

[84] Hemachandra LP, Shin DH, Dier U, Iuliano JN, Engelberth SA, Uusitalo LM, et al. Mitochondrial Superoxide Dismutase Has a Protumorigenic Role in Ovarian Clear Cell Carcinoma. Cancer Res. 2015; 75: 4973-84.

[85] Anwar S, Alrumaihi F, Sarwar T, Babiker AY, Khan AA, Prabhu SV, et al. Exploring Therapeutic Potential of Catalase: Strategies in Disease Prevention and Management. Biomolecules. 2024; 14: 697.

[86] Giustarini D, Milzani A, Dalle-Donne I, Rossi R. How to Increase Cellular Glutathione. Antioxidants. 2023; 12: 1094.

[87] Xia C, Xing X, Zhang W, Wang Y, Jin X, Wang Y, et al. Cysteine and homocysteine can be exploited by GPX4 in ferroptosis inhibition independent of GSH synthesis. Redox Biol. 2024; 69: 102999.

[88] Carr AC, Frei B. Toward a new recommended dietary allowance for vitamin C based on antioxidant and health effects in humans. Am J Clin Nutr. 1999; 69: 1086-107.

[89] DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature. 2011; 475: 106-9.

[90] Galadari S, Rahman A, Pallichankandy S, Thayyullathil F. Reactive oxygen species and cancer paradox: To promote or to suppress? Free Radic Biol Med. 2017; 104: 144-64.

[91] Uddin T. Oxidative genomic or genotoxic stress in neurodegeneration: Mechanisms and therapeutic avenues. AIMS Neurosci. 2025; 12: 369-90.

[92] Vostrikova SM, Grinev AB, Gogvadze VG. Reactive Oxygen Species and Antioxidants in Carcinogenesis and Tumor Therapy. Biochem (Mosc). 2020; 85: 1254-66.

[93] Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature. 2009; 461: 1071-8.

[94] Zeman MK, Cimprich KA. Causes and consequences of replication stress. Nat Cell Biol. 2013; 16: 2-9.

[95] Ma W, Zhou S. Metabolic Rewiring in the Face of Genomic Assault: Integrating DNA Damage Response and Cellular Metabolism. Biomolecules. 2025; 15: 168.

[96] Moazamian A, Saez F, Drevet JR, Aitken RJ, Gharagozloo P. Redox-Driven Epigenetic Modifications in Sperm: Unraveling Paternal Influences on Embryo Development and Transgenerational Health. Antioxidants. 2025; 14: 570.

[97] An X, Yu W, Liu J, Tang D, Yang L, Chen X. Oxidative cell death in cancer: mechanisms and therapeutic opportunities. Cell Death Dis. 2024; 15: 556.

[98] Balamurli G, Liew AQX, Tee WW, Pervaiz S. Interplay between epigenetics, senescence and cellular redox metabolism in cancer and its therapeutic implications. Redox Biol. 2024; 78: 103441.

[99] Aggarwal V, Tuli HS, Varol A, Thakral F, Yerer MB, Sak K, et al. Role of Reactive Oxygen Species in Cancer Progression: Molecular Mechanisms and Recent Advancements. Biomolecules. 2019; 9: 735.

[100] Ashourpour M, Mostafavi Hosseini F, Amini M, Saeedian Moghadam E, Kazerouni F, Arman SY, et al. Pyrazole Derivatives Induce Apoptosis via ROS Generation in the Triple Negative Breast Cancer Cells, MDA-MB-468. Asian Pac J Cancer Prev. 2021; 22: 2079-87.

[101] Heppner DE. Structural insights into redox-active cysteine residues of the Src family kinases. Redox Biol. 2021; 41: 101934.

[102] Arfin S, Jha NK, Jha SK, Kesari KK, Ruokolainen J, Roychoudhury S, et al. Oxidative Stress in Cancer Cell Metabolism. Antioxidants. 2021; 10: 642.

[103] Jomova K, Alomar SY, Valko R, Fresser L, Nepovimova E, Kuca K, et al. Interplay of oxidative stress and antioxidant mechanisms in cancer development and progression. Arch Toxicol. 2025; 100: 27-73.

[104] Jiang J, Peng L, Wang K, Huang C. Moonlighting Metabolic Enzymes in Cancer: New Perspectives on the Redox Code. Antioxid Redox Signal. 2021; 34: 979-1003.

[105] Lee CJ, Yoon H. Metabolic Adaptation and Cellular Stress Response As Targets for Cancer Therapy. World J Men's Health. 2024; 42: 62-70.

[106] Yu JS, Cui W. Proliferation, survival and metabolism: the role of PI3K/AKT/mTOR signalling in pluripotency and cell fate determination. Development. 2016; 143: 3050-60.

[107] Ryoo IG, Lee SH, Kwak MK. Redox Modulating NRF2: A Potential Mediator of Cancer Stem Cell Resistance. Oxidative Med Cell Longev. 2015; 2016: 2428153.

[108] Lubrano V, Balzan S. LOX-1 and ROS, inseparable factors in the process of endothelial damage. Free Radic Res. 2014; 48: 841-8.

[109] Jain RK. Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia. Cancer Cell. 2014; 26: 605-22.

[110] Hamad DS, Soleimani A, Said KM. Targeting Redox-Dependent Signaling Pathways for Cancer Treatment: Opportunities and Challenges. J Med Chem Sci. 2026; 9: 96-110.

[111] Parisi E, Sorolla A, Montal R, González-Resina R, Novell A, Salud A, et al. Prognostic Factors Involved in the Epithelial-Mesenchymal Transition Process in Colorectal Cancer Have a Preponderant Role in Oxidative Stress: A Systematic Review and Meta-Analysis. Cancers. 2020; 12: 3330.

[112] Shen T, Wang Y, Cheng L, Bode AM, Gao Y, Zhang S, et al. Oxidative complexity: The role of ROS in the tumor environment and therapeutic implications. Bioorg Med Chem. 2025; 127: 118241.

[113] Chan JS, Tan MJ, Sng MK, Teo Z, Phua T, Choo CC, et al. Cancer-associated fibroblasts enact field cancerization by promoting extratumoral oxidative stress. Cell Death Dis. 2017; 8: e2562.

[114] Kennel KB, Greten FR. Immune cell - produced ROS and their impact on tumor growth and metastasis. Redox Biol. 2021; 42: 101891.

[115] Peinado H, Zhang H, Matei IR, Costa-Silva B, Hoshino A, Rodrigues G, et al. Pre-metastatic niches: organ-specific homes for metastases. Nat Rev Cancer. 2017; 17: 302- 17.

[116] Kotsafti A, Scarpa M, Castagliuolo I, Scarpa M. Reactive Oxygen Species and Antitumor Immunity-From Surveillance to Evasion. Cancers. 2020; 12: 1748.

[117] Sena LA, Chandel NS. Physiological Roles of Mitochondrial Reactive Oxygen Species. Mol Cell. 2012; 48: 158-67.

[118] Bradley CA. Stem cells - masters of their fates. Nat Rev Cancer. 2017; 17: 574-5.

[119] Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic Cell Death in Cancer Therapy. Annu Rev Immunol. 2013; 31: 51-72.

[120] Manda G, Nechifor MT, Neagu TM. The redox biology network in cancer pathophysiology and therapeutics. Redox Biol. 2015; 5: 347-57.

[121] Chio IIC, Tuveson DA. ROS in Cancer: The Burning Question. Trends Mol Med. 2017; 23: 411-29.

[122] Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov. 2009; 8: 579-91.

[123] Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev. 2012; 2012: CD007176.

[124] Firczuk M, Bajor M, Graczyk-Jarzynka A, Fidyt K, Goral A, Zagozdzon R. Harnessing altered oxidative metabolism in cancer by augmented prooxidant therapy. Cancer Lett. 2020; 471: 1-11.

[125] Samoylenko A, Hossain JA, Mennerich D, Kellokumpu S, Hiltunen JK, Kietzmann T. Nutritional Countermeasures Targeting Reactive Oxygen Species in Cancer: From Mechanisms to Biomarkers and Clinical Evidence. Antioxid Redox Signal. 2013; 19: 2157-96.

[126] Hayes JD, Dinkova-Kostova AT, Tew KD. Oxidative Stress in Cancer. Cancer Cell. 2020; 38: 167-97.

[127] Fath MA, Diers AR, Aykin-Burns N, Simons AL, Hua L, Spitz DR. Mitochondrial electron transport chain blockers enhance 2-deoxy-D-glucose induced oxidative stress and cell killing in human colon carcinoma cells. Cancer Biol Ther. 2014; 8: 1228-36.

[128] Shen ZX, Shi ZZ, Fang J, Gu BW, Li JM, Zhu YM, et al. All-trans retinoic acid/As₂O₃ combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci. 2004; 101: 5328-35.

[129] O'Day SJ, Eggermont AM, Chiarion-Sileni V, Kefford R, Grob JJ, Mortier L, et al. Final Results of Phase III SYMMETRY Study: Randomized, Double-Blind Trial of Elesclomol Plus Paclitaxel Versus Paclitaxel Alone As Treatment for Chemotherapy-Naive Patients With Advanced Melanoma. J Clin Oncol. 2013; 31: 1211-8.

[130] Chen D, Cui QC, Yang H, Dou QP. Disulfiram, a Clinically Used Anti-Alcoholism Drug and Copper-Binding Agent, Induces Apoptotic Cell Death in Breast Cancer Cultures and Xenografts via Inhibition of the Proteasome Activity. Cancer Res. 2006; 66: 10425-33.

[131] Panieri E, Santoro MM. ROS homeostasis and metabolism: a dangerous liason in cancer cells. Cell Death Dis. 2016; 7: e2253.

[132] Roh JL, Kim EH, Jang H, Shin D. Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis. Redox Biol. 2017; 11: 254-62.

[133] Harris IS, Treloar AE, Inoue S, Sasaki M, Gorrini C, Lee KC, et al. Glutathione and Thioredoxin Antioxidant Pathways Synergize to Drive Cancer Initiation and Progression. Cancer Cell. 2015; 27: 211-22.

[134] Raza MH, Siraj S, Arshad A, Waheed U, Aldakheel F, Alduraywish S, et al. ROS-modulated therapeutic approaches in cancer treatment. J Cancer Res Clin Oncol. 2017; 143: 1789-809.

[135] Stockwell BR, Friedmann Angeli JP, Bayir H, Bush AI, Conrad M, Dixon SJ, et al. Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease. Cell. 2017; 171: 273-85.

[136] Hou D, Liu Z, Xu X, Liu Q, Zhang X, Kong B, et al. Increased oxidative stress mediates the antitumor effect of PARP inhibition in ovarian cancer. Redox Biol. 2018; 17: 99-111.

[137] Ge M, Luo J, Wu Y, Shen G, Kuang X. The biological essence of synthetic lethality: Bringing new opportunities for cancer therapy. MedComm - Oncol. 2024; 3: e3.

[138] Čepelak I, Dodig S, Dodig DČ. Ferroptosis: regulated cell death. Arch Ind Hyg Toxicol. 2020; 71: 99-109.

[139] Maiorino M, Conrad M, Ursini F. GPx4, Lipid Peroxidation, and Cell Death: Discoveries, Rediscoveries, and Open Issues. Antioxid Redox Signal. 2018; 29: 61-74.

[140] Bersuker K, Hendricks JM, Li Z, Magtanong L, Ford B, Tang PH, et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature. 2019; 575: 688-92.

[141] Mao C, Liu X, Zhang Y, Lei G, Yan Y, Lee H, et al. DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer. Nature. 2021; 593: 586-90.

[142] Hou W, Xie Y, Song X, Sun X, Lotze MT, Zeh HJ 3rd, et al. Autophagy promotes ferroptosis by degradation of ferritin. Autophagy. 2016; 12: 1425-8.

[143] Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature. 2009; 458: 780-3.

[144] Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. 2016; 17: 97-111.

[145] Liou GY, Storz P. Reactive oxygen species in cancer. Free Radic Res. 2010; 44: 479-96.

[146] Wang L, Kuang Z, Zhang D, Gao Y, Ying M, Wang T. Reactive oxygen species in immune cells: A new antitumor target. Biomed Pharmacother. 2021; 133: 110978.

[147] Hurst KE, Lawrence KA, Essman MT, Walton ZJ, Leddy LR, Thaxton JE. Endoplasmic Reticulum Stress Contributes to Mitochondrial Exhaustion of CD8+ T Cells. Cancer Immunol Res. 2019; 7: 476-86.

[148] Shabbir MA, Hao H, Shabbir MZ, Hussain HI, Iqbal Z, Ahmed S, et al. Survival and Evolution of CRISPR-Cas System in Prokaryotes and Its Applications. Front Immunol. 2016; 7: 375.

[149] Kim KS, Song CG, Kang PM. Targeting Oxidative Stress Using Nanoparticles as a Theranostic Strategy for Cardiovascular Diseases. Antioxid Redox Signal. 2019; 30: 733-46.

[150] Liang J, Liu B. ROS-responsive drug delivery systems. Bioeng Transl Med. 2016; 1: 239-51.

[151] Yang B, Chen Y, Shi J. Reactive Oxygen Species (ROS)-Based Nanomedicine. Chem Rev. 2019; 119: 4881-985.

[152] Li Y, Yang J, Sun X. Reactive Oxygen Species-Based Nanomaterials for Cancer Therapy. Front Chem. 2021; 9: 650587.

[153] Kobayashi H, Turkbey B, Watanabe R, Choyke PL. Cancer Drug Delivery: Considerations in the Rational Design of Nanosized Bioconjugates. Bioconjugate Chem. 2014; 25: 2093-100.

[154] Fosse V, Oldoni E, Bietrix F, Budillon A, Daskalopoulos EP, Fratelli M, et al. Recommendations for robust and reproducible preclinical research in personalised medicine. BMC Med. 2023; 21: 14.

[155] Dirnagl U, Duda GN, Grainger DW, Reinke P, Roubenoff R. Reproducibility, relevance and reliability as barriers to efficient and credible biomedical technology translation. Adv Drug Deliv Rev. 2022; 182: 114118.

[156] Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021; 22: 266-82.

[157] Stockwell BR. Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications. Cell. 2022; 185: 2401-21.

[158] Glorieux C, Liu S, Trachootham D, Huang P. Targeting ROS in cancer: rationale and strategies. Nat Rev Drug Discov. 2024; 23: 583-606.

[159] Reczek CR, Chandel NS. The Two Faces of Reactive Oxygen Species in Cancer. Annu Rev Cancer Biol. 2017; 1: 79-98.

[160] Zhang S, Xiao X, Yi Y, Wang X, Zhu L, Shen Y, et al. Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets. Signal Transduct Target Ther. 2024; 9: 149.

[161] Rosenbauer J, Berghoff M, Glazier JA, Schug A. Multiscale Modeling of Spheroid Tumors: Effect of Nutrient Availability on Tumor Evolution. J Phys Chem B. 2023; 127: 3607-15.

[162] Verza FA, DA Silva GC, Nishimura FG. The impact of oxidative stress and the NRF2-KEAP1-ARE signaling pathway on anticancer drug resistance. Oncol Res. 2025; 33: 1819-34.

[163] Sherwood AM, Yasseen BA, DeBlasi JM, Caldwell S, DeNicola GM. Distinct roles for the thioredoxin and glutathione antioxidant systems in Nrf2-Mediated lung tumor initiation and progression. Redox Biol. 2025; 83: 103653.

[164] Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov. 2013; 12: 931-47.

[165] Nazari A, Osati P, Seifollahy Fakhr S, Faghihkhorasani F, Ghanaatian M, Faghihkhorasani F, et al. New Emerging Therapeutic Strategies Based on Manipulation of the Redox Regulation Against Therapy Resistance in Cancer. Antioxid Redox Signal. 2024: ars20230491.

[166] Murphy MP, Bayir H, Belousov V, Chang CJ, Davies KJA, Davies MJ, et al. Guidelines for measuring reactive oxygen species and oxidative damage in cells and in vivo. Nat Metab. 2022; 4: 651-62.

[167] Catalano T, Selvaggi F, Cotellese R, Aceto GM. The Role of Reactive Oxygen Species in Colorectal Cancer Initiation and Progression: Perspectives on Theranostic Approaches. Cancers. 2025; 17: 752.

[168] Liu Y, Wu G, Feng L, Li J, Xia Y, Guo W, et al. Harnessing Antioxidants in Cancer Therapy: Opportunities, Challenges, and Future Directions. Antioxidants. 2025; 14: 674.

[169] Khan AQ, Rashid K, AlAmodi AA, Agha MV, Akhtar S, Hakeem I, et al. Reactive oxygen species (ROS) in cancer pathogenesis and therapy: An update on the role of ROS in anticancer action of benzophenanthridine alkaloids. Biomed Pharmacother. 2021; 143: 112142.

[170] Yang J, Bai L, Shen M, Gou X, Xiang Z, Ma S, et al. A Multiple Stimuli-Responsive NanoCRISPR Overcomes Tumor Redox Heterogeneity to Augment Photodynamic Therapy. ACS Nano. 2023; 17: 11414-26.

[171] Brenneisen P, Reichert AS. Nanotherapy and Reactive Oxygen Species (ROS) in Cancer: A Novel Perspective. Antioxidants. 2018; 7: 31.

[172] Mitra S, Nguyen LN, Akter M, Park G, Choi EH, Kaushik NK. Impact of ROS Generated by Chemical, Physical, and Plasma Techniques on Cancer Attenuation. Cancers. 2019; 11: 1030.